SK Bioscience is aggressively looking at acquisitions of a vaccine firm as well as a cell and gene therapy (CGT) manufacturing firm in the US with a possibility of reaching deals as early as this year.
Following its growth strategy announced last year, the vaccine specialist affiliate of the SK Group allocated KRW2.4tn ($1.8bn) in R&D and other investments over the next five years, sharply up from KRW460bn spent in the past five years
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?